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Abstract
Physiologically during puberty and adolescence, when juvenile acne usually appears, the 
response to a glucose load is increased if compared to the one observed in adult and at 
pre-pubertal  age, while insulin sensitivity is reduced.  Insulin is a hormone that acts at  
different levels along the axis which controls the sex hormones. It increases the release of 
LH and FSH by pituitary gland, stimulates the synthesis of androgens in the gonads and 
stimulates the synthesis of androgenic precursors in adrenal glands. Finally, it acts in the 
liver by inhibiting the synthesis of Sex Hormone Binding Globulin (SHBG). Insulin is also 
able to act directly on the production of sebum and amplify the effects of Iinsulin Growth  
Factor-1 in the skin, inhibiting the synthesis of its binding protein (IGF Binding Protein-1). 
In female subjects with acne and Polycystic Ovary Syndrome (PCOS),  insulin resistance 
is  a  well  known  pathogenetic  factor,  while  the  relationship  between  acne  and  insulin 
resistance has been poorly investigated in males so far. 
The purpose of this study is to investigate the correlation between insulin resistance and 
acne in young males who do not respond to common therapy. Clinical and biochemical 
parameters of  glucose, lipid metabolism, androgens and IGF-1 were evaluated. Insulin 
resistance  was  estimated  by  Homeostasis  Model  assessment  (HOMA-IR)  and  Oral 
Glucose Tolerance Test was also performed.  We found that subjects with acne had higher 
Sistolic and Diastolic Blood Pressure, Waist/Hip Ratio, Waist Circumference, 120' OGTT 
serum insulin and serum IGF-1 and lower HDL-cholesterol than subjects of comparable 
age and gender without acne.
The results thus obtained confirmed what other authors have recently reported about a 
metabolic imbalance in young males with acne. Furthermore, these results support the 
hypothesis  that  insulin  resistance might  play an important  role  in  the  pathogenesis  of 
treatment-resistant acne in males. 
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1.1 Polycystic Ovary Syndrome model
In 1990 the National Institute of Child Health and Human Disease (NICHD) of the United 
States National Institutes of Health (NIH) defined Policystic Ovary (or Ovarian) Syndrome 
(PCOS) as a syndrome which should include (in order of importance): 
1. hyperandrogenism and/or hyperandrogenemia;
2. oligo-ovulation, [and the] 
3. exclusion of other known disorders, which could cause hyperandrogenism.
This  survey  had  the  clarity  of  identifying  PCOS  as  an  androgen  excess  disorder  of 
exclusion, with ovarian consequences. 
Under the NIH/NICHD criteria, clinical hyperandrogenism has generally been interpreted 
as hirsutism, since >70% of hirsute women are hyperandrogenemic. Consequently, three 
principal phenotypes were originally recognized: 
1. women with hirsutism, hyperandrogenemia, and oligo-ovulation; 
2. women with hirsutism and oligo- ovulation; 
3. women with hyperandrogenemia and oligo- ovulation. 
According to the NIH/NICHD criteria, the presence of polycystic ovaries by ultrasound was 
suggestive, but not diagnostic, of PCOS.
In 2003 a new consensus was established by the European Society for Human 
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Reproduction and Embryology and the American Society for Reproductive Medicine in 
Rotterdam which defined the syndrome as the presence of at least two of the following 
three features: 
1. oligo- and/or anovulation; 
2. clinical and/or biochemical signs of hy- perandrogenism;
3. polycystic ovaries on ultrasound.  
According to the Rotterdam criteria, the population of potential patients with the PCOS has 
increased  through  the  creation  of  two  new  phenotypes,  namely,  patients  who  have 
polycystic ovaries, hirsutism, and/or hyperandrogenemia but normal ovulation and women 
who have polycystic ovaries and irregular ovulation but no sign of androgen excess. 
Finally,  in 2006 the Androgen Excess Society and  Polycystic Ovary Syndrome Society 
gave emphasis to hyperandrogenism, suggesting that this would be a mandatory criterion 
for the diagnosis of the syndrome.  
Even if  the  definition  of  PCOS is  still  debated,  PCOS is  the  most  frequent  endocrine 
disorder that is associated with acne. Its prevalence is around 15-20% in infertile women.  
Furthermore,  PCOS  is  a  good  example  of  coexistence  of  insulin  resistance, 
hyperandrogenism and hyperinsulinemia. Indeed, in female with acne and PCOS, insulin 
resistance is a well known etiopathogenetic factor. 
The insulin receptor in PCOS is genetically and functionally normal. Insulin resistance in 
PCOS  is  caused  by  a  post-receptor  defect  in  insulin  signaling  with  increased  serine 
phosphorylation implicated as the cause of decreased insulin-stimulated Iinsulin Receptor 
Substrate-1 (IRS-1) activation and decreased GLUT 4 expression. 
Although  insulin  resistance  per  se  is  considered  to  be  the  responsible  entity  for 
5
hyperandrogenism in  PCOS,  this  mechanism does  not  explain  the  hyperandrogenism 
evident  in  women with  the disorder  without  insulin  resistance and/or  excess adiposity. 
Inflammation  may be the  common thread in  the induction  of  insulin  resistance that  is 
related to PCOS per se, or to superimposed excess adiposity. 
This concept raises the possibility that inflammation may be capable of directly inducing 
hyperandrogenism  in  PCOS.  The  ability  of  TNF-alpha  to  stimulate  increased  serine 
phosphorylation makes it an ideal candidate for initiating these molecular events in PCOS. 
Furthermore,  while  discussing  the  definition  of  PCOS  and  the  validity  of  the  criteria  
proposed for its diagnosis, some authors observed that the only presence of polycystic 
ovaries  in  women  who  otherwise  are  not  hirsute  and  have  normal  ovulation  can  be 
associated with the presence of features reminiscent of those observed in patients with  
PCOS.  This  features  include mild  elevations in  circulating  LH ,  androgen,  and insulin 
levels,  in  insulin  resistance  assessed  using  the  homeostatic  assessment  (HOMA-IR) 
calculation  or  the  insulin  tolerance  test,  and  in  the  LH,  17-hydroxyprogesterone,  and 
testosterone response to acute long-acting GnRH-analog stimulation. 
There  are  some evidence that  hyperandrogenemic  ovulatory women with  and  without 
polycystic ovaries did not have significantly different androgen levels and LH/FSH ratios, 
although the former had higher fasting insulin levels, lower glucose-insulin ratios, and a 
higher 17-hydroxyprogesterone response to leuprolide. 
These data suggest  that  hyperandrogenemic  ovulatory women with  polycystic  ovaries, 
whether hirsute or not, tend to have mild insulin resistance and mild evidence of ovarian 
dysfunction, although significantly less than women with anovulatory PCOS. 
Other investigators found that fasting and glucose-stimulated insulin and glucose levels or 
gonadotropin levels were similarly altered in non hyperandrogenic women with polycystic  
ovaries and in patients with PCOS. In both groups, menstrual irregularity was associated 
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with  significantly  higher  concentrations  of  serum fasting  and  stimulated  insulin  levels, 
independent of androgens and degree of obesity. 
In conclusion, PCOS well represents the complexity of interaction between androgens and 
insulin/IGF-1 and can be used as a model of the complex interaction between immune and 
endocrine system.
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1.2 Growth Hormone (GH) and Insulin-like Growth Factors (IGFs) in acne
Growth Hormone is secreted by the pituitary gland and acts on the liver and peripheral  
tissues to stimulate the production of IGFs (Insulin-like Growth Factors). They are formerly 
known as somatomedins.  Growth hormone is released in  intermittent  secretory bursts; 
IGF-1 is relatively stable instead.
IGF is found in two forms, IGF-1 (the most prevalent) and IGF-2. Adolescence is a time of 
maximal growth hormone secretion. Furthermore, in adolescence the highest serum levels 
of IGF-1 are reached. In addition, IGF-1 can be produced locally within the skin, where it 
can interact with receptors on the sebaceous gland to stimulate its growth. 
In some tissues, the actions of IGF-1 can be mediated by androgens and it  has been 
hypothesized that androgens may influence IGF-1 action in the sebaceous gland as well.  
Sebocytes express receptors for growth factors, including Epidermal Growth Factor (EGF) 
and IGF-1. 
All known functions of IGF-1 are mediated by its cell membrane receptor. The distribution 
of the IGF-1 receptor in normal and pathological tissue provides valuable clues to its role 
in vivo. 
Hodak et al. demonstrated that IGF-1 receptor was expressed not only in the epidermis 
but also in several skin appendages. IGF-1 immunoreactivity was found in the outer root 
sheath, hair matrix cells, sebaceous gland, eccrine sweat duct, and myoepithelial cells of 
the  secretory portion  of  eccrine  sweat  gland.  IGF-1  receptor  in  a  cell  surface pattern 
occurred principally in undifferentiated epithelial  cells in both the epidermis and in skin 
appendages. In normal epidermis, in hyperplastic epidermis, and within the pilosebaceous 
unit,  the  expression  of  IGF-1  receptors  by undifferentiated  epithelial  cells  was  largely 
coincident with proliferating or cyclig cell populations, as assessed by expression of the 
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Ki67 nuclear protein. 
Ligand-mediated activation of the IGF-1 receptor is required for proliferative responses of 
cutaneous epithelial cells to other mitogens such as EGF, basic-Fibroblast Growth Factor 
(bFGF), or Keratinocyte Growth Factor (KGF) and restricted expression of IGF-1 receptors 
to  relatively  undifferentiated  epithelial  cells  could  directly  explain  compartmentialized 
proliferation.
In pilosebaceous epithelia IGF-1 receptor immunoreactivity is localized to the basal layer 
of  the outer root sheath and the germinative layer of  sebaceous gland, whereas EGF 
receptor  immunoreactivity is  observed in  all  cells  of  outer  root  sheath and sebaceous 
gland. The presence of IGF-1 receptor expression in sweat duct epithelium, as well as 
myoepithelial  cells,  which are metabolically very active but mitotically inactive indicates 
that IGF-1 receptor expression in the skin is not restricted to structures that are greatly 
involved in cell replication. IGF-1 is not only a mitogenic factor, but also a factor regulating 
the synthetic activity of a variety of cells. 
The  influence  of  sex  steroids  on  the  folliculo-sebaceous  unit  is  well  established,  and 
several lines of evidence link IGF-1 with sex hormones.
There is increasing evidence suggesting the involvement of IGF-1 in acne. Recent studies 
describe a correlation between IGF-1 serum levels and the severity of acne in women 
(Aizawa and Niimura, 1995; Cappel et al., 2005). IGF-1 serum levels also correlate directly 
with the amount of facial sebum in both men and women (Vora et al. 2008). 
In the skin, IGF-1 induces keratinocyte proliferation in vitro and in vivo, and it induces lipid 
production in human sebocytes. 
Isard et al. found that IGF-1 and IGF1-R were overexpressed in acne lesions as compared 
with healthy skin. They have firstly reported that Propionibacterium acnes stimulates IGF-1 
and IGF-1R expression in keratinocytes and increases IGF-1 secretion. Furthermore, they 
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observed that  IGF-1  and IGF-1R overexpression  in  acne lesions was  associated  with 
increase in Ki-67 and filaggrin expression in the epidermis, confirming that IGF-1/IGF-1R 
system  is  associated  with  the  modulation  of  both  proliferation  and  differentiation  of 
keratinocytes. 
Therefore, acne has been recently suggested to be an IGF-1 mediated disease. 
IGF-1 production activate IGF-1R, mostly located in the basal layer of epidermis, and thus 
induce proliferation  of  keratinocytes  and an increase in  filaggrin  expression  through a 
paracrine  pathway.  Moreover,  acne  lesion  formation  is  increased  by  the  induction  of 
lipogenesis and the production of androgens by IGF-1. 
Similar to that of growth hormone and IGF1, the level of dehydroepiandrosterone sulphate 
(DHEAS), that is the major adrenal androgen precursor, progressively increases during 
puberty.  It  appears  to  be  a  crucial  factor  in  the  initiation  of  sebum  secretion  in  the  
prepubertal period and perhaps beyond. IGF-1 and DHEAS follow a similar chronological 
trend, for this reason some authors hypothesized a possible relationship between these 
two hormones. 
Cappel et al. studied the correlation between IGF-1 and DHT and DHEAS in an all-women 
group, a group of women with clinical acne, and a group of men with clinical acne. Their  
study supported the findings that IGF-1 levels are higher in adult women with acne than in 
those without acne. Furthermore, they found statistically significant correlations between 
IGF-1 and DHEAS and IGF-1 and DHT in the all-women group, statistically correlation 
between dihydrotestosterone (DHT) and IGF-1 in women with clinical acne and statistically 
correlation between DHEAS and androstenedione levels in men with clinical acne. 
Despite  these  correlations,  the  data  from  their  study  demonstrate  that  IGF-1  and 
androgens can act independently or dependently on acne lesions counts, depending on 
the patient group or subgroup. However,  in men and women with clinical  acne,  IGF-1 
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appears to play a greater role. Moreover, in women with clinical acne, IGF-1 actually acted 
independently of androgens. 
A correlation between the mean facial sebum excretion rate and serum IGF-1 levels has 
been demonstrated in postadolescent acne patients as well.
Figure 1.  Regulatory network of ACTH, LH, GH, IGF-1 in adrenal and gonadal androgen synthesis and 
cutaneous  intracrine  androgen  metabolism.  (AR=androgen  receptor)  [Melnik  et  al.,  Experimental  Dermatology,  
2009;18:833-841]
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1.3 The regulatory network of GH, Insulin and IGF-1 
GH, insulin and IGF-1 have distinct effects on sebocyte growth and differentiation. 
IGF-1 exerts its major effect on proliferation, while having an effect similar to insulin on 
differentiation. 
More than 90% of circulating IGFs are bound to IGF- binding protein-3 (IGFBP-3), the rest 
to IGFBP-1, -2, -4, -5 and -6, and less than 1% of IGFs circulate as free IGFs. 
IGF signal transduction is mediated by the IGF-1 receptor (IGF1R) and IGF2R. The IGF1R 
is a tyrosine kinase receptor, which is able to form heterodimers with insulin receptor (IR).  
The IGF2R is a scavenger receptor involved in the degradation of IGF-2. Insulin primarily 
binds to IR, but it can also bind to IGF1R. Furthermore, insulin at high levels, as found in 
insulin-resistant subjects, can interact with the IGF-1R. 
Figure 2. IGF-1, IGF-2 and insulin signal transduction and receptor cross-reactivity inducing mitogenic 
responses. (IR=insulin receptor) [Melnik et al., Experimental Dermatology, 2009;18:833-841]
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IGF-1 and IGF-2 primarily bind to their specific receptors but are also able to bind to IR,  
explaining the significant overlap in signal transduction. IGF1R-mediated signals activate 
the Ras-Raf-MAP kinase and the phospho-inositide 3-kinase (PI3K) ⁄ Akt pathway. The IR-
B isoform mediates the classic metabolic responses induced upon insulin binding and has 
very low affinity for IGFs. Activation of the IR-A isoform by either insulin or IGF-2 leads to  
mitogenic responses similar to those observed for IGF1R.
In immortalized human sebaceous gland cell lines SEB-1, IGF-1 increased lipogenesis by 
the induction of sterol response element-binding protein-1(SREBP-1). 
SREBP-1 preferentially regulates genes of fatty acid synthesis. 
In  the  hamster  ear  sebaceous  model,  androgens  rapidly  induced  the  expression  of 
SREBP-1. Insulin regulates SREBP-1 on the trascriptional level. The importance of IGF-1 
for lipid synthesis in immortalized human sebaceous gland cell lines SZ sebocytes and for 
keratinocyte proliferation has been demonstrated. 
In human SEB-1 sebocytes, IGF-1 activated PI3K/Akt and MAPK /ERK-signal transduction 
pathways  and  induced  the  expression  SREBP-1  resulting  in  increased  sebaceous 
lipogenesis. Addition of a specific PI3K-inhibitor down-regulated IGF-1-induced expression 
of SREBP-1 and sebaceous lipogenesis. 
SREBP-1c increases also in response to insulin signalling. 
SREBP-1 has been implicated in  the  development  of  insulin  resistance and regulates 
components of the insulin signalling pathway such as IRS-2 and PI3KR3. All the recently 
identified promoters of the human genome, which bind SREBP-1 and its two associated 
transcription factors Sp1 and NFY, form an interconnected regulatory circuit and bind to 
distinct sets of target genes. Members of the Sp-family may be key mediators of gene 
expression induced by insulin. Insulin regulates the subcellular localization, stability and 
trans-activation potential of Sp1 (29). 
13
Figure 3. IGF-1 signalling in the pilosebaceous follicle and related interaction with androgen metabolism, 
androgen-dependent  FGF-FGFR2b-signalling,  endocrine  and  nutritional  impact  on  IGF-1  homeostasis. 
(MAPK=mitogen-activated  protein  kinase;  PI3K=phosphoinositide-3-kinase)  [Melnik  et  al.,  Experimental  
Dermatology, 2009;18:833-841]
The  role  of  androgen-dependent  FGFR2b  signalling  in  keratinocyte  and  sebocyte 
differentiation in acne has been recently elaborated. 
IGF1R  primarily  regulates  cellular  proliferation  and  to  a  lesser  extent  differentiation, 
whereas FGFR2b is predominantly involved in cellular differentiation. 
Comedogenesis is considered to be a process of increased keratinocyte proliferation as 
well  as  exaggerated  keratinocyte  differentiation  (hyperkeratinization).  From  studies  on 
human keratinocyte cell culture models, it has been concluded that the normalizing activity  
of  retinoids  on  diseases  with  hyperkeratinization  is  mediated  by  modulation  of 
differentiation rather than cell growth. 
IGF1R expressed on basal cells, and FGFR2b expressed on suprabasal cells, regulate 
canonical cellular pathways involved in proliferation and differentiation of sebocytes and 
14
keratinocytes  and  activate  MAPK-  and  PI3K  ⁄  Akt  signalling  pathways.  Substantial 
qualitative overlap in their  recruitment profiles has been demonstrated. The androgen-
dependent expression of FGF7 and FGF10, the ligands of FGFR2b, is increased by IGF-1- 
mediated Androgen Receptor signalling. 
In this regard, IGFR1-signalling has cooperative effects for FGFR2b signal transduction. 
IGF-1 induces androgen receptor (AR) trans-activation. In the nucleus, AR binds to the AR 
repressive protein Foxo1. IGF-1, as well  as insulin activates PI3K, which leads to Akt-
mediated Foxo1 phosphorylation. Phosphorylated Foxo1 leaves the AR and translocates 
from the nucleus into the cytoplasm. By this mechanism, IGF-1 signalling alleviates AR 
repression  resulting  in  AR  gain-of-function.  Thus,  IGF-1  has  direct  influence  on  the 
intracrine  androgen  regulation  of  the  skin  and  potentiates  androgen  signalling  by  the 
induction of 5a-reductase activity and activation of AR. 
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1.4 Insulin resistance
Insulin resistance is characterized by decreased cellular uptake of glucose and normal or 
increased serum levels of insulin. 
In  states  of  insulin  resistance,  the  intracellular  pool  of  the  insulin-responsive  glucose 
transporter  4  (GLUT4)  is  markedly  reduced.  GLUT4  proteins  are  stored  in  recycling 
endosomes  until  insulin  stimulates  the  cell  to  deliver  large  numbers  of  recycling 
endosomes with GLUT4 to the plasma membrane to facilitate increased glucose uptake. 
However,  in  insulin-resistant  states,  higher  than  normal  insulin  levels  are  required  to 
increase the membrane pool of GLUT4 for adequate glucose uptake. 
The improvement in insulin sensitivity normalizes increased insulin levels. 
As  insulin  is  a  stimulator  of  hepatic  IGF-1  secretion,  the  insulin-lowering  effect  of 
metformin will reduce elevated serum IGF-1 levels. 
SREBP-1c is also regulated at the transcriptional level by insulin.
In obesity-related diabetic syndromes, TNFa is a known mediator of insulin resistance by 
causing increased serine phosphorylation of insulin receptor substrate-1 (IRS-1) in insulin 
sensitive tissues.  This  leads to decreased expression of GLUT 4, the insulin  sensitive 
glucose transport protein. 
As already said in section 1.1, Insulin Receptor (IR) in PCOS is genetically and functionally 
normal. Insulin resistance in PCOS is caused by a post-receptor defect in insulin signaling 
with  increased  serine  phosphorylation  implicated  as  the  cause  of  decreased  insulin-
stimulated IRS-1 activation and decreased GLUT 4 expression. Thus, the ability of TNF-
alpha  to  stimulate  increased  serine  phosphorylation  makes  it  an  ideal  candidate  for  
initiating these molecular events in PCOS. 
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Endocrine diseases or nutritional influences leading to increased insulin and IGF-1 serum 
levels are frequently associated with acne. 
It  has been well  documented that immune processes are modulated by the endocrine 
system. In fact, glucocorticoid hormones have potent anti-inflammatory properties on cells 
of the innate immune system. TNFalpha-induced insulin resistance is the most studied 
example of interaction of immune and endocrine systems. It was first described in the early 
1990s. It is now known that proinflammatory cytokines also induce a state of resistance in 
other important hormone systems, including glucocorticoids, GH, and IGF-1. 
The  intracellular  signaling  components  for  both  proinflammatory  cytokine  and  IGF 
receptor-activated  pathways  are  present  in  most  cell  types,  and  are  sometimes  even 
shared (ERK-1/2 for both IGF-I and proinflammatory cytokine). This situation creates the 
potential  for  signal  amplification or  resistance.  However,  in  the case of  insulin,  TNF-R 
activated pathways are well  known to  engage in intracellular crosstalk and reduce the 
availability  of  substrates  used  by  insulin  receptor-activated  pathways,  resulting  in 
resistance. At least two proinflammatory cytokine-activated pathways interact with IGF-IR 
signaling to impair the induction of PI3-K dependent events. 
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1.5 The role of Insulin and IGF-1 in the pathogenesis of acne
Acne is associated with sebaceous gland hyperactivity.  Sebum has been shown to be 
comedogenic and can cause inflammation when injected cutaneously.
The increase of sebum production coincides with adrenarche. Indeed, androgens play an 
important role in increasing the sebaceous gland size, stimulating sebum production and 
stimulating keratinocyte proliferation in the pilosebaceous unit. 
In addition to androgen in the serum, it is known that insulin-like growth factor-1 (IGF-1) 
levels correlate with severity of acne in women. Serum IGF-1 levels are also known to be  
the highest during puberty, which is when sebum production begins and this coincides with  
the  occurrence  of  acne.  Vora  et  al.  have  recently  observed  that  exists  a  correlation 
between the amount of mean facial sebum excretion (MFSE) and serum IGF-1. Moreover, 
this seem to be true in both men and women. 
Increased IGF-1 could lead to increased sebum secretion. It was also noted that serum 
IGF-1 levels correlated with acne lesion counts in women, but not in men. 
In acne patients,  associations between serum levels of  IGF-1, dehydroepiandrosterone 
sulphate, dihydrotestosterone, acne lesion counts and facial sebum secretion rate have 
been reported. IGF-1 stimulates 5a-reductase, adrenal and gonadal androgen synthesis, 
androgen receptor signal transduction, sebocyte proliferation and lipogenesis.
The  number  of  total  acne  lesions,  inflammatory  lesions,  serum  levels  of 
dihydrotestosterone  (DHT)  and  dehydroepiandrosterone  sulphate  (DHEAS),  each 
correlated with serum IGF-1 levels in women with acne. 
IGF-1 enhances the sensitivity of the adrenal for ACTH, and induces the expression and 
activity of key enzymes of adrenal androgen biosynthesis. In healthy prepubertal girls as 
well as prepubertal girls with premature adrenarche, a positive correlation between IGF-1 
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and DHEAS serum levels has been reported. Serum IGF-1 levels rise and fall in a pattern 
similar  to  serum DHEAS,  and normal  puberty  is  characterized by a  state  of  transient 
insulin  resistance  associated  with  an  increase  in  gonadal  sex  steroid  production  and 
adrenal androgens. 
Addition  of  IGF-1  to  cultures  of  rat  and  human  skin  scrotal  fibroblasts  significantly 
increased 5a-reductase activity in a dose-dependent manner. Conversion of testosterone 
to  DHT increases  androgen  signalling.  The  IGF-1-induced  activation  of  5a-reductase 
points to an important role of IGF-1 as a peripheral amplifier of androgen metabolism in 
the skin. 
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2.1 Introduction
Physiologically during puberty and adolescence, when juvenile acne usually appears, the 
response to a glucose load is increased when compared to the one observed in adult and 
at pre-pubertal age, while insulin sensitivity is reduced. Insulin is a hormone that acts at 
different levels along the axis which controls the sex hormones. It increases the release of 
LH and FSH by pituitary gland, stimulates the synthesis of androgens in the gonads and 
stimulates the synthesis of androgenic precursors in adrenal glands. Finally, it acts in the 
liver by inhibiting the synthesis of Sex Hormone Binding Globulin (SHBG). It  was also 
demonstrated that insulin is able to act directly on the production of sebum and amplify the 
effects of  IGF-1 in the skin,  inhibiting the synthesis of  its binding protein (IGF binding 
protein-1, IGFBP- 1). Therefore, disturbances in insulin metabolism may contribute to the 
occurrence of acne.
In clinical practice treatment-resistant acne is not a so rare event. We identify two groups 
of  patients  in  which  acne  does  not  seem  primarily  due  to  a  disorder  of  androgen 
hormones. In the first group there are female patients who have persistent acne or late-
onset acne. In these patients blood concentrations of androgens are frequently normal and 
their treatment-resistant acne seems not to be strictly related to hyperandrogenism. 
The  second  group  of  patients  is  composed  by male  subjects  who  present  treatment-
resistant acne. We decided to focus our attention on the latter group of patients because 
the  relationship  between  acne  and  insulin  resistance  has  been  poorly  investigated  in 
males so far.  
On the basis of recent findings that have demonstrated the role of insulin and IGF-1 in the  
pathogenesis of acne vulgaris, we assumed that IGF-1 and insulin could have a key role in 
treatment resistance development in these subjects. 
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2.2 Methods
Our observational study was performed in a population of males aged 15-26 years, with 
treatment-resistant inflammatory acne. We classified as resistant those patients suffering 
from acne for at least a year, who didn't experience in the latter six months any clinical  
improvement, despite adherence to all therapies prescribed according to the most recent 
guidelines for acne therapy. 
Insulin  resistance was estimated by HOMA-IR.  In  subjects  with  HOMA-IR higher  than 
normal  and/or  fasting  glucose  higher  than  normal  and  insulin  levels  was  performed 
evaluation  of  glucose  tolerance  by  OGTT  (glucose  loading  test  at  0  and  120  'after 
administration of 75 g of glucose).
In a second step, the dosage of IGF-1, insulin and the calculation of insulin resistance by 
HOMA-IR was performed on a population of female patients not previously selected with 
PCOS and with  androgen levels  within  normal  limits,  assuming the role  of  IGF-1 and 
insulin in the resistance to treatment.
At the dermatological examination, acne was classified according to the degree of disease 
in  mild-moderate-severe  acne  by  a  global  acne  grading  system  (GAGS).  The  GAGS 
considers six locations on the face and chest/upper back, with a factor for each location 
based toughly on surface area, distribution, and density of pilosebaceous units. The global 
score is the summation of all local scores (0 = None, 1–18 = Mild, 19–30 = Moderate, 31–
38 = Severe, >39 = Very severe). 
21
Figure 4. The six locations (I-VI) of the Global Acne Grading System (GAGS) 
[Doshi A, et al.Int J Dermatol 1997;36:416-18]
Height,  weight,  body  mass  index  (BMI),  waist  circumference  (WC),  waist  to  hip  ratio 
(WHR), and measurements of systolic (SBP) and diastolic blood pressure (DBP) were 
evaluated by standard methods. BMI was measured as the ratio between the weight and 
the square of the height. A BMI between 25 and 30 was considered as index of overweight  
while >30 was considered as index of obesity. WC was measured as the smallest trunk 
circumference between the twelfth rib and the iliac crest. WHR was measured as the ratio 
between the WC and the circumference of the hip, considered as the maximal extension of 
the buttocks. The measurements were performed with the patients in standing position 
with  relaxed  abdomen,  arms  at  sides,  and  joined  feet.  WHR>0.8  in  females  and 
WHR>0.95 in males are considered abnormal values. 
Blood pressure was measured in the right arm, with the subjects in relaxed sitting position. 
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In all subjects, serum blood samples were obtained by standard methods to measure total 
(total-cholesterol  <200 mg/dl)  and high density lipoprotein  cholesterol  (HDL-cholesterol 
>45 mg/dl), triglycerides (<180 mg/dl), glycemia (60–110 mg/dl), insulin (5–20 μU/ml), and 
glycated hemoglobin (<6 %). An oral glucose tolerance test (OGTT) was also performed 
(75 g of glucose diluted in 250 ml of saline solution, measuring blood glucose every 30 
minutes  for  2  hours).  Insulin  resistance was  estimated by HOMA-IR.  The  relationship 
between glucose and insulin is well known and has led to the development of the index  
HOMA (Homeostasis Model Assessment). The HOMA is a mathematical model by which 
insulin sensitivity can be calculated starting from the simultaneous concentrations of serum 
fasting glucose and serum fasting insulin.
The index of  insulin  resistance by homeostasis  model  assessment  (HOMA-IR)  is  also 
based on a mathematical model that allows to quantify the extent of insulin resistance.
For calculating HOMA-IR was used the formula published by Matthews:
HOMA-IR = [basal insulin (μU / mL x fasting glucose (mg/ dL)] / 405
Normal range = 0.23 to 2.5 (average 0.99) 
In subjects with HOMA-IR higher than normal and/or fasting glucose and/or insulin higher  
than normal an oral glucose tolerance test (OGTT) was also performed (75 g of glucose 
diluted  in  250 ml  of  saline  solution,  measuring  blood glucose every 30  minutes  for  2 
hours). The hormonal work-up included free testosterone (15–40 μg/ml), total testosterone 
(10.4–34.7 nmol/l), dehydroepiandrosterone sulfate (DHEAS; 35–430 μg/dl), sex hormone-
binding globulin (SHBG; 6–50 nmol/l),  and Insulin-like Growth Factor 1 (IGF-1; 90–280 
mg/ml), which were evaluated by standard methods using commercially available kits. 
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Inclusion criteria:
- Males aged 15-16 with treatment-resistant inflammatory acne of the face and/or body
- BMI≤ 24,9
- Good general health
- No usual intake of drugs (except acne therapy)
- Blood Pressure <140/90 mmHg
Exclusion criteria:
- Patients affected by Diabetes Mellitus Type 1 or Type 2 (Criteria for the diagnosis of  
Type 2 Diabetes Mellitus: fasting glucose≥126 mg/dL in two different measurements or 
blood  glucose>  200  mg/dL in  a  single  occasion  and  in  the  presence  of  suggestive 
symptoms)
- Patients affected by other dermatological diseases or performing treatment for other 
endocrinopathies
24
2.3 Results
Seven patients were recruited according to our inclusion criteria.
By comparing the 7 subjects with data from a group of controls of comparable age and 
gender, we found that patients had higher Sistolic and Diastolic Blood Pressure, Waist/hip 
Ratio, Waist Circumference, 120' OGTT serum insulin and serum IGF-1. HDL-cholesterol 
was higher in controls than in subjects with acne. 
These difference did not achieve statistical significance perhaps owing to our small sample 
size, but our pilot study supports the findings previously reported by Del Prete et al. 
These authors observed a significant correlation between acne score and HOMA-IR, 120' 
OGTT serum glucose levels, serum IGF-1 levels, in a group of 13 subjects with treatment-
resistant acne and BMI≤ 24,9. 
Fig 5. Comparison of mean concentrations of Fig 6. Comparison of mean concentrations of
serum glucose for each time of OGTT in subjects serum insulin for each time of OGTT in subjects
with acne and subjects without acne(*) with acne and subjects without acne(*)
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These  authors  investigated  the  relationship  betweeen  acne  and  insulin  resistance  in  
males,  comparing 22 young males with  acne and 22 controls  of  comparable age and 
gender. They found that patients had higher BMI (p = 0.003), WC (p = 0.002), WHR (p = 
0.02), SBP (p = 0.0001), DBP (p = 0.001), basal (p = 0.01) and 120 minutes OGTT serum 
insulin concentrations (p = 0.002), basal glucose concentrations (p = 0.03), HOMA-IR (p = 
0.016),  and  lower  HDL-cholesterol  than  controls  (p  =  0.001).  Total  cholesterol, 
triglycerides, serum IGF-1, and androgen levels were similar in subjects with acne and 
controls. Baseline serum insulin and glucose concentrations were significantly higher in 
subjects with acne. In parallel, OGTT curves were significantly different between subjects 
with acne and controls (Figs. 5,6 ). At 120 min. OGTT, serum glucose levels were similar 
between subjects with  acne and controls,  while  serum insulin  levels  were significantly 
higher in sub- jects with acne than in controls. 
The same authors performed a subgroup analysis by excluding subjects with 
overweight/obesity (BMI >24.9). At the linear correlation study, among the 13 subjects with 
acne and BMI>24.9, they found a significant correlation between acne score and HOMA-
IR, 120 min. OGTT serum glucose levels, serum IGF-1 levels.  
Moreover, they reported that HDL-cholesterol (p = 0.05) and 120 min. OGTT serum insulin 
concentrations (p = 0.009) resulted to be independent predictors of acne at multivariate 
analysis. 
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Table  1.  Clinical  and metabolic  characteristics  of  subjects  with and without  acne: whole population with 
BMI<24.9 (Data are reported as Mean ± SEM. P<0,05 are considered significant)
Subjects with acne Subjects without acne P (Wilcoxon 
test)
Age 18,6 ± 3 20 ± 3,1 0,1
BMI (Kg/m2) 22,2 ± 2,1 20,7 ± 1,7 0,1
WC (cm) 83,3 ± 10 79,4 ± 7,6 0,02
WHR 0,8 ± 0,05 0,7 ± 0,07 0,04
SBP (mmHg) 128,1 ± 7,9 112,5 ± 9 0,0001
DBP (mmHg) 80,9 ± 6,4 72,9 ± 7,8 0,03
Fasting serum glucose (mg/dL) 87,3 ± 8,6 84,3 ± 6,3 0,3
Fasting serum insulin (μU/mL) 10,3 ± 9,2 5,2 ± 1,2 0,09
120' OGTT serum glucose (mg/dL) 84,3 ± 21,6 83,3 ± 9,7 0,05
120' OGTT serum insulin (μU/mL) 20,5 ± 14,7 7,6 ± 1,2 0,009
HOMA-IR 1,5 ± 0,7 1,1 ± 0,3 0,05
Total cholesterol (mg/dL) 179,5 ± 32,2 165,0 ± 19,4 0,2
HDL cholesterol (mg/dL) 47,1 ± 7,2 58,8 ± 8,3 0,05
Tryglicerides (mg/dL) 85,1 ± 19,5 83,6 ± 15,3 0,83
Serum IGF-1 (nmol/L) 325,3 ± 97,2 318,3 ± 6,7 0,03
Free testosterone (pg/mL) 22,6 ± 19,8 21 ± 18,8 0,8
Total testosterone (ng/dL) 5,4 ± 1,6 5,4 ± 1,4 0,9
DHEAS (μg/dL) 222,6 ± 116,5 180,5 ± 167,9 0,46
SHBG (nmol/L) 32,4 ± 8,9 32,8 ± 7,8 0,9
Legend. BMI:body mass index, WHR:waist/hip ratio, HOMA-IR:Homeostasis Model assessment of insulin 
resistance;  SBP:systolic  blood  pressure;  DBP=diastolic  blood  pressure;  DHEAS:dehydroepiandrosterone 
sulfate, SHBG:sex-hormone-binding globulin, WC:waist circumference, OGTT: oral glucose tolerance test (*)
(*)Del Prete M, et al. Insulin-resistance and acne: a new risk factor for men? Endocrine 2012;42:555-60.
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2.4 Discussion
The purpose of this study was to investigate a possible correlation between acne and 
insulin  resistance in  a  sample  of  acneic  treatment-resistant  males,  who were  in  good 
general health, apart from their dermatological condition. 
According  to  the  inclusion  criteria  shown above,  we  decided to  exclude  patients  who 
presents a metabolic syndrome to avoid this bias. 
To make the diagnosis of Metabolic Syndrome at least two of the following criteria are 
required: 
-the presence of abdominal obesity which is defined for Europeans >94 cm in men; 
-serum triglycerides >150 mg/dl, 
-cholesterol levels HDL <40 mg/dl (in men) or lipid-lowering therapy, 
-blood pressure >130/85 mmHg or antihypertensive treatment, and 
-fasting glucose >100 mg/dl or previous diagnosis of Diabetes Mellitus Type 2.
In female subjects with acne and PCOS, insulin resistance is a well known pathogenetic 
factor, while males have been poorly studied so far. 
In all  males with acne here evaluated, the androgenic profile was found to be normal, 
suggesting that acne in these patients can be related to changes in insulin and IGF-1 
circulating levels rather than to changes in androgen levels, unlike female subjects with 
acne and PCOS who have hyperinsulinemia and hyperandrogenism.  
Our data, even with the limits of a pilot study, support the hypothesis that insulin resistance 
might play an important role in the development of acne in males who are no responders 
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to common therapies. Our data confirmed the results which have been recently reported 
by Del Prete et al. and suggest that young acneic males should be investigated for insulin 
sensitivity to start a dietary and/or pharmacological treatment options. 
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